Aegis Therapeutics LLC

Type: Company
Name: Aegis Therapeutics LLC
First reported Mar 19 2014 - Updated Mar 19 2014 - 1 reports

Bioavailability Breakthrough: Aegis’ enhancement tech works in pill form

Aegis Therapeutics claims a technology developed to improve the bioavailability of drugs delivered through the nose has a similar solubility enhancement effect in a solid dosage form.The California, US-based firm announced it had applied its Intravail ... [Published In-Pharmatechnologist - Mar 19 2014]
First reported Mar 12 2014 - Updated Mar 12 2014 - 2 reports

Aegis Intravail(R) Technology Enhances Oral Bioavailability of Tableted OTC Drugs

- Aegis Therapeutics LLC's Intravail® technology has been successfully formulated with phenylephrine in compressed tablets, dramatically improving oral bioavailability by more than 50%. This is the first application of Intravail® in a solid dosage form. ... [Published 4 Traders - Mar 12 2014]
First reported Feb 06 2014 - Updated Feb 06 2014 - 1 reports

Aegis awarded its first patent for oral delivery of nucleotide-based drugs

Aegis Therapeutics has been awarded its first patent for oral delivery of nucleotide analog based drugs based upon the company’s patented Intravail transmucosal absorption enhancer technology.US patent No. 8,642,564 provides methods for oral delivery ... [Published Pharmaceutical Business Review - Feb 06 2014]
First reported Feb 05 2014 - Updated Feb 05 2014 - 1 reports

Aegis Awarded Its First Patent for Oral Delivery of Nucleotide-Based Drugs With High Bioavailability

SAN DIEGO, CA--(Marketwired - Feb 5, 2014) - Aegis Therapeutics LLC announced today that it has been awarded its first patent for oral delivery of nucleotide analog based drugs based upon Aegis' patented Intravail® transmucosal absorption enhancer technology. U.S. ... [Published Marketwire - Breaking News Releases - Feb 05 2014]

More Content

All (6) | News (4) | Reports (0) | Blogs (2) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Bioavailability Breakthrough: Aegis’ enhancemen... [Published In-Pharmatechnologist - Mar 19 2014]
Aegis Intravail(R) Technology Enhances Oral Bio... [Published 4 Traders - Mar 12 2014]
Aegis Intravail(R) Technology Enhances Oral Bio... [Published Marketwire - Breaking News Releases - Mar 12 2014]
Aegis awarded its first patent for oral deliver... [Published Pharmaceutical Business Review - Feb 06 2014]
Aegis Awarded Its First Patent for Oral Deliver... [Published Marketwire - Breaking News Releases - Feb 05 2014]
Aegis wins New Zealand patent for fast acting f... [Published Pharmaceutical Business Review - Aug 15 2013]
1
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Aegis Intravail(R) Technology Enhances Oral Bio... [Published Marketwire - Breaking News Releases - Mar 12 2014]
SAN DIEGO, CA--(Marketwired - Mar 12, 2014) - Aegis Therapeutics LLC's Intravail® technology has been successfully formulated with phenylephrine in compressed tablets, dramatically improving oral bioavailability by more than 50%. This is the first application ...
Aegis Awarded Its First Patent for Oral Deliver... [Published Marketwire - Breaking News Releases - Feb 05 2014]
SAN DIEGO, CA--(Marketwired - Feb 5, 2014) - Aegis Therapeutics LLC announced today that it has been awarded its first patent for oral delivery of nucleotide analog based drugs based upon Aegis' patented Intravail® transmucosal absorption enhancer technology. U.S. ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.